KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) Revenue (2016 - 2025)

Historic Revenue for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $1.6 billion.

  • Edwards Lifesciences' Revenue rose 1467.07% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 billion, marking a year-over-year increase of 1059.57%. This contributed to the annual value of $5.4 billion for FY2024, which is 857.29% up from last year.
  • According to the latest figures from Q3 2025, Edwards Lifesciences' Revenue is $1.6 billion, which was up 1467.07% from $1.5 billion recorded in Q2 2025.
  • Edwards Lifesciences' Revenue's 5-year high stood at $1.6 billion during Q3 2025, with a 5-year trough of $429.9 million in Q4 2022.
  • For the 5-year period, Edwards Lifesciences' Revenue averaged around $1.3 billion, with its median value being $1.3 billion (2024).
  • Its Revenue has fluctuated over the past 5 years, first crashed by 6766.94% in 2022, then soared by 19458.01% in 2023.
  • Quarter analysis of 5 years shows Edwards Lifesciences' Revenue stood at $1.3 billion in 2021, then plummeted by 67.67% to $429.9 million in 2022, then surged by 194.58% to $1.3 billion in 2023, then increased by 9.43% to $1.4 billion in 2024, then rose by 12.07% to $1.6 billion in 2025.
  • Its Revenue was $1.6 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.4 billion in Q1 2025.